Inventiva

IVA

Market cap $1.2B

Inventiva S.A. (IVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

The mean of analysts' price targets for Inventiva (IVA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Daix (France), New York City (New York, United States) , February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its certain preliminary unaudited financial results for the full year ending December 31, 2025, including cash, cash equivalents, and revenues.

Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference.

A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for ​betting on the loss-making French biotech, which is on the verge of entering the fast-growing treatment market for liver disease ‌MASH.

Does Inventiva S.A. Sponsored ADR (IVA) have what it takes to be a top stock pick for momentum investors?

Inventiva S.A. (IVA) Presents at 44th Annual J.P.

The consensus price target hints at a 200.6% upside potential for Inventiva (IVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its cash position as of September 30, 2025 and its revenues for the first nine months of 2025.

Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01, have exercised in full their option (the "Underwriters' Option") to purchase 5,844,155 additional ADSs (the "Additional ADSs"). The additional ADSs are expected to be delivered on November 18, 2025.